MARK SCHREIBER: Open Payments
NPI 1124090022 · VIRGINIA BEACH, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,747 in 98 payments from 15 companies in 2025. Trend: 2023 $2,289 · 2024 $1,739 · 2025 $1,747
Food & beverage: $1,747
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 22 | $496 |
| ABBVIE INC. | 22 | $322 |
| Otsuka America Pharmaceutical, Inc. | 13 | $200 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $156 |
| Janssen Pharmaceuticals, Inc | 4 | $110 |
| Neurocrine BioSciences, Inc. | 3 | $70 |
| Vanda Pharmaceuticals Inc. | 4 | $67 |
| Alkermes, Inc. | 3 | $62 |
| Axsome Therapeutics, Inc. | 4 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
Products named: COBENFY, VRAYLAR, CAPLYTA, REXULTI, INVEGA SUSTENNA, ABILIFY ASIMTUFII, INGREZZA, FANAPT.
Industry payments across VA — which companies pay providers there.
